
Infection reports Volume 8 Number 29 Published on: 25 July 2014

Immunisation appendix

Annual report from the sentinel surveillance study of blood borne virus testing in England: supplementary tables for January to December 2013 and map of surveillance centres

Map of sentinel surveillance centres in 2013



1. Hepatitis A IgM testing

Supplementary table 1. Number of individuals tested, and testing positive, for anti-HAV IgM in participating centres, January – December 2013*

PHE centre	Number tested	Number positive (%)
Anglia and Essex	2,232	7 (0.3)
Avon, Gloucestershire and Wiltshire	2,953	18 (0.6)
Cheshire and Merseyside	1,288	13 (1.0)
Cumbria and Lancashire	1,270	5 (0.4)
East Midlands	4,252	5 (0.1)
Greater Manchester	1,645	5 (0.3)
London	6,451	36 (0.6)
North East	1,116	5 (0.4)
Sussex, Surrey and Kent	3,395	11 (0.3)
Wessex	262	0 (0.0)
West Midlands	943	11 (1.2)
Yorkshire and Humber	3,278	8 (0.2)
Total	29,085	124 (0.4)

* Excludes reference testing and testing from hospitals referring all samples. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

Supplementary table 2. Number of individuals tested, and testing positive, for anti-HAV IgM in participating
centres, January - December 2013* [†]

	Fe	emale	Γ	lale	Unl	known	-	Total
Age group	Number tested	Number positive (%)						
Under 1 year	115	0 (0.0)	147	0 (0.0)	0	0 (0.0)	262	0 (0.0)
1-14 years	341	12 (3.5)	412	15 (3.6)	1	0 (0.0)	754	27 (3.6)
15-24 years	1,564	10 (0.6)	1,725	7 (0.4)	9	0 (0.0)	3,298	17 (0.5)
25-34 years	2,091	6 (0.3)	2,874	15 (0.5)	14	0 (0.0)	4,979	21 (0.4)
35-44 years	1,675	4 (0.2)	2,983	5 (0.2)	5	0 (0.0)	4,663	9 (0.2)
45-54 years	2,168	2 (0.1)	2,816	5 (0.2)	8	0 (0.0)	4,992	7 (0.1)
55-64 years	2,043	5 (0.2)	2,087	6 (0.3)	3	0 (0.0)	4,133	11 (0.3)
≥65 years	2,926	24 (0.8)	3,985	9 (0.3)	4	0 (0.0)	5,915	32 (0.5)
Unknown	36	0 (0.0)	52	0 (0.0)	1	0 (0.0)	89	0 (0.0)
Total, all age groups	12,959	63 (0.5)	16,081	61 (0.4)	45	0 (0.0)	29,085	124 (0.4)

* Excludes reference testing and testing from hospitals referring all samples. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

Supplementary table 3. Number of individuals tested and testing positive for anti-HAV by ethnic group, January – December 2013*

Ethnic group	Number tested	Number positive (%)
Asian or Asian British origin	3,525	40 (1.1)
Black or Black British origin	474	2 (0.4)
Other and/or mixed origin	765	2 (0.3)
White or White British origin	23,517	78 (0.3)
Unknown ethnic origin	805	2 (0.2)
Total	29,085	124 (0.4)

* Excludes reference testing and testing from hospitals referring all samples. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

2. Hepatitis B surface antigen testing

a. Antenatal HBsAg screening

Supplementary table 4. Number of women tested, and testing positive for HBsAg through antenatal screening in participating centres, January – December 2013*

PHE centre	Number tested	Number positive (%)
Anglia and Essex	4,473	8 (0.2)
Avon, Gloucestershire and Wiltshire	9,124	11 (0.1)
Cheshire and Merseyside	7,558	16 (0.2)
Cumbria and Lancashire	2,393	5 (0.2)
East Midlands	418	8 (1.9)
Greater Manchester	7,305	20 (0.3)
London	13,239	122 (0.9)
North East	2,309	13 (0.6)
Sussex, Surrey and Kent	7,179	19 (0.3)
Wessex	2,442	4 (0.2)
West Midlands	7,842	4 (0.1)
Yorkshire and Humber	8,550	37 (0.4)
Total	72,832	267 (0.4)

* Excludes dried blood spot testing, oral fluid testing, reference testing and testing from hospitals referring all samples. Only women aged 12-49 years old are included. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

b. Non-antenatal HBsAg testing

Supplementary table 5. Number of individuals tested, and testing positive for HBsAg in participating centres (excluding antenatal testing), January –December 2013*

PHE centre	Number tested	Number positive (%)
Anglia and Essex	8,686	75 (0.9)
Avon, Gloucestershire and Wiltshire	18,282	108 (0.6)
Cheshire and Merseyside	11,602	128 (1.1)
Cumbria and Lancashire	3,223	32 (1.0)
East Midlands	13,220	114 (0.9)
Greater Manchester	19,892	213 (1.1)
London	89,648	1,313 (1.5)
North East	9,956	87 (0.9)
Sussex, Surrey and Kent	11,494	128 (1.1)
Wessex	4,722	38 (0.8)
West Midlands	9,225	54 (0.6)
Yorkshire and Humber	18,604	201 (1.1)
Total	218,554	2,491 (1.1)

* Excludes antenatal screening, dried blood spot testing, oral fluid testing, reference testing and testing from hospitals referring all samples. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

Supplementary table 6. Age and gender of individuals tested for HBsAg in participating centres (excluding antenatal testing), January - December 2013*

	Fe	emale		Male	Un	known	Г	otal
Age group	Number tested	Number positive (%)						
Under 1 year	390	2 (0.5)	485	7 (1.4)	198	3 (1.5)	1,073	12 (1.1)
1-14 years	1,948	11 (0.6)	2,133	22 (1.0)	25	0 (0.0)	4,106	33 (0.8)
15-24 years	21,334	132 (0.6)	19,054	189 (1.0)	646	13 (2.0)	41,034	335 (0.8)
25-34 years	31,854	260 (0.8)	32,288	571 (1.8)	508	11 (2.2)	64,650	842 (1.3)
35-44 years	17,198	182 (1.1)	23,084	460 (2.0)	268	8 (3.0)	40,550	650 (1.6)
45-54 years	11,232	105 (0.9)	15,305	256 (1.7)	125	3 (2.4)	26,662	364 (1.4)
55-64 years	7,789	47 (0.6)	9,566	98 (1.0)	38	0 (0.0)	17,393	146 (0.8)
≥65 years	10,206	33 (0.3)	11,884	70 (0.6)	26	1 (3.8)	22,116	104 (0.5)
Unknown	184	3 (1.6)	313	4 (1.3)	473	0 (0.0)	970	7 (0.7)
Total, all age groups	102,135	775 (0.8)	114,112	1677 (1.5)	2,307	39 (1.7)	218,554	2491 (1.1)

* Excludes dried blood spot, oral fluid, reference testing and testing from hospitals referring all samples. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

3. Hepatitis C antibody testing

Supplementary table 7. Number of individuals tested, and testing positive for anti-HCV in participating centres, January – December 2013*

PHE centre	Number tested	Number positive (%)
Anglia and Essex	8,262	94 (1.1)
Avon, Gloucestershire and Wiltshire	16,125	265 (1.6)
Cheshire and Merseyside	12,555	332 (2.6)
Cumbria and Lancashire	3,249	97 (3.0)
East Midlands	10,903	208 (1.9)
Greater Manchester	14,177	264 (1.9)
London	72,357	1,269 (1.8)
North East	10,265	106 (1.0)
Sussex, Surrey and Kent	11,043	269 (2.4)
Wessex	4,185	56 (1.3)
West Midlands	8,489	137 (1.6)
Yorkshire and Humber	16,754	334 (2.0)
Total	188,364	3,431 (1.8)

* Excludes dried blood spot testing, oral fluid testing, reference testing and testing from hospitals referring all samples. Excludes individuals aged less than one year, in whom positive tests may reflect the presence of passively-acquired maternal antibody rather than true infection. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

Supplementary table 8. Age and gender of individuals tested for anti-HCV in participating centres, January - December 2013*								
	Fe	emale	N	lale	Unk	nown	Total	
Age group	Number tested	Number positive (%)						
1-14	1,501	1 (0.1)	1,643	5 (0.3)	21	0 (0.0)	3,165	6 (0.2)
15-24	14,805	84 (0.6)	14,683	112 (0.8)	573	1 (0.2)	30,061	197 (0.7)
25-34	23,875	296 (1.2)	27,851	552 (2.0)	451	14 (3.1)	52,177	862 (1.7)
35-44	15,127	233 (1.5)	22,057	677 (3.1)	252	13 (5.2)	37,436	9,263 (2.5)
45-54	10,391	212 (2.0)	15,037	560 (3.7)	117	12 (10.3)	25,545	784 (3.1)
55-64	7,719	118 (1.5)	9,361	304 (3.2)	35	2 (5.7)	17,115	424 (2.5)
≥65	10,249	82 (0.8)	11,659	131 (1.1)	21	0 (0.0)	21,929	213 (1.0)
Unknown	169	0 (0.0)	304	20 (6.6)	463	2 (0.4)	936	22 (2.4)
Total, all age groups	83,943	1026 (1.2)	102,595	2364 (2.3)	1,933	44 (2.3)	188,364	3438 (1.8)

* Excludes dried blood spot, oral fluid reference testing and testing from hospitals referring all samples. Individuals aged less than one year are excluded since positive tests in this age group may reflect the presence of passively-acquired maternal antibody rather than true infection. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

4. Hepatitis D total antibody testing

Supplementary table 9. Number of individuals tested, and testing positive, for HDV-TA and/or HDV IgM in participating centres, January – December 2013*

PHE centre	Number tested	Number positive (%)
Anglia and Essex	181	6 (3.3)
Avon, Gloucestershire and Wiltshire	25	2 (8.0)
Cheshire and Merseyside	20	2 (10.0)
Cumbria and Lancashire	10	0 (0.0)
Devon, Cornwall and Somerset	10	1 (10.0)
East Midlands	165	7 (4.2)
Greater Manchester	121	5 (4.1)
London	980	41 (4.2)
North East	67	4 (6.0)
South Midlands and Hertfordshire	34	3 (8.8)
Sussex, Surrey and Kent	89	5 (5.6)
Thames Valley	73	2 (2.7)
Wessex	43	4 (9.3)
West Midlands	95	5 (5.3)
Yorkshire and Humber	191	10 (5.2)
Total	2,104	97 (4.6)

* Excludes reference testing. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

5. Hepatitis E IgM testing

Supplementary table 10. Number of individuals tested, and testing positive, for anti-HEV IgM in participating centres, January – December 2013*

PHE centre	Number tested	Number positive (%)
Anglia and Essex	849	49 (5.8)
Avon, Gloucestershire and Wiltshire	120	52 (43.3)
Cheshire and Merseyside	115	14 (12.2)
Cumbria and Lancashire	76	6 (7.9)
Devon, Cornwall and Somerset	347	50 (14.4)
East Midlands	492	33 (6.7)
Greater Manchester	639	13 (2.0)
London	2,229	112 (5.0)
North East	117	12 (10.3)
South Midlands and Hertfordshire	373	22 (5.9)
Sussex, Surrey and Kent	389	22 (5.7)
Thames Valley	403	16 (4.0)
Wessex	222	31 (14.0)
West Midlands	1,202	54 (4.5)
Yorkshire and Humber	544	37 (6.8)
Total	8,117	523 (6.4)

* Excludes reference testing. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

6. HIV testing

a. Antenatal HIV screening

Supplementary table 11. Number of women tested, and testing positive for HIV through antenatal screening in participating centres, January – December 2013*

PHE centre	Number tested	Number positive (%)
Anglia and Essex	4,118	2 (0.0)
Cheshire and Merseyside	6,130	4 (0.1)
London	23,859	36 (0.2)
North East	2,789	5 (0.2)
Sussex, Surrey and Kent	7,153	5 (0.1)
Wessex	2,425	1 (0.0)
West Midlands	7,844	8 (0.1)
Yorkshire and Humber	5,823	7 (0.1)
Total	60,141	68 (0.1)

* Excludes dried blood spot testing, oral fluid testing, reference testing and testing from hospitals referring all samples. Only women aged 16-49 years old are included. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional. Data are presented for PHEC where testing coverage is broadly representative of the PHEC as a whole.

b. Non-antenatal HIV testing

Supplementary table 12. Number of adults (16+ years old) tested, and testing positive for HIV in participating centres (excluding antenatal testing), January – December 2013*

PHE centre	Number tested	Number positive (%)
Anglia and Essex	11,721	47 (0.4)
Avon, Gloucestershire and Wiltshire	28	2 (7.1)
Cheshire and Merseyside	15,240	97 (0.6)
Cumbria and Lancashire	5,252	29 (0.6)
East Midlands	20,057	76 (0.4)
Greater Manchester	29,657	295 (1.0)
London	141,922	1,331 (0.9)
North East	18,198	67 (0.4)
Sussex, Surrey and Kent	30,178	293 (1.0)
Wessex	11,611	52 (0.4)
West Midlands	14,537	108 (0.7)
Yorkshire and Humber	20,858	148 (0.7)
Total	319,242	2,545 (0.8)

* Excludes individuals aged under 16, antenatal screening, dried blood spot testing, oral fluid testing, reference testing and testing from hospitals referring all samples. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

Supplementary table 13. Age and gender of adults (16+ years old) tested for HIV in participating centres (excluding antenatal testing), January - December 2013*

	F	emale	Male		Unknown		Total	
Age group	Number tested	Number positive (%)						
16-24 years	56,557	77 (0.1)	41,311	220 (0.5)	1,463	6 (0.4)	99,331	303 (0.3)
25-34 years	56,861	160 (0.3)	53,925	654 (1.2)	1,115	7 (0.6)	111,901	821 (0.7)
35-44 years	23,646	196 (0.8)	27,994	556 (2.0)	499	5 (1.0)	52,139	757 (1.5)
45-54 years	11,293	103 (0.9)	15,727	368 (2.3)	214	3 (1.4)	27,234	474 (1.7)
55-64 years	5,148	36 (0.7)	8,158	103 (1.3)	61	1 (1.6)	13,367	140 (1.0)
≥65 years	5,878	14 (0.2)	8,290	29 (0.3)	25	0 (0.0)	14,193	43 (0.3)
Unknown	281	1 (0.4)	322	6 (1.9)	474	0 (0.0)	1,077	7 (0.6)
Total, all age groups	159,664	587 (0.4)	155,727	1,936 (1.2)	3,851	22 (0.6)	319,242	2,545 (0.8)

* Excludes individuals aged under 16, antenatal screening, dried blood spot testing, oral fluid testing, reference testing and testing from hospitals referring all samples. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

7. HTLV testing

Supplementary table 14. Number of individuals tested, and testing positive, for HTLV in participating centres, January – December 2013*

PHE centre	Number tested	Number positive (%)
Avon, Gloucestershire and Wiltshire	21	0 (0.0)
Cheshire and Merseyside	135	1 (0.7)
Cumbria and Lancashire	176	2 (1.1)
Devon, Cornwall and Somerset	2	0 (0.0)
East Midlands	11	1 (9.1)
Greater Manchester	1,370	6 (0.4)
London	2,619	67 (2.6)
North East	494	0 (0.0)
South Midlands and Hertfordshire	39	2 (5.1)
Sussex, Surrey and Kent	622	4 (0.6)
Thames Valley	64	2 (3.1)
Wessex	210	1 (0.5)
West Midlands	358	10 (2.8)
Yorkshire and Humber	108	4 (3.7)
Avon, Gloucestershire and Wiltshire	21	0 (0.0)
Total	6,904	101 (1.5)

* Excludes reference testing. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

Supplementary table 15. Number of individuals tested, and testing positive, for HTLV in participating centres, January - December 2013*

	Fe	emale	Male Uni		le Male Unknowr		known		Total	
Age group	Number tested	Number positive (%)								
Under 1 year	33	2 (6.1)	35	4 (11.4)	9	0 (0.0)	77	6 (7.8)		
1-14 years	103	2 (1.9)	159	4 (2.5)	27	0 (0.0)	289	6 (2.1)		
15-24 years	253	2 (0.8)	267	0 (0.0)	60	0 (0.0)	580	2 (0.3)		
25-34 years	612	7 (1.1)	497	5 (1.0)	52	0 (0.0)	1,161	12 (1.0)		
35-44 years	437	2 (0.5)	500	6 (1.2)	28	0 (0.0)	965	8 (0.8)		
45-54 years	537	12 (2.2)	673	11 (1.6)	9	0 (0.0)	1,219	23 (1.9)		
55-64 years	532	15 (2.8)	667	8 (1.2)	3	1 (33.3)	1,202	24 (2.0)		
≥65 years	487	12 (2.5)	587	6 (1.0)	1	0 (0.0)	1,075	18 (1.7)		
Unknown	25	2 (8.0)	50	0 (0.0)	261	0 (0.0)	336	2 (0.6)		
Total, all age groups	3,019	56 (1.9)	3,435	44 (1.3)	450	1 (0.2)	6,904	101 (1.5)		

* Excludes reference testing. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

8. Dried blood spot testing

a. HBsAg testing

Supplementary table 16. Number of individuals tested, and testing positive, for HBsAg by dried blood spot, January – December 2013*

	Data from sentinel surveillance [§]		Data from Alere Toxicology Plc [†]		Total	
PHE centre of test request	Number tested	Number positive (%)	Number tested	Number reactive [†] (%)	Number tested	Number reactive (%)
Anglia and Essex	74	0 (0.0)	443	5 (1.1)	517	5 (1.0)
Avon, Gloucestershire and Wiltshire	313	1 (0.3)	142	4 (2.8)	455	5 (1.1)
Cheshire and Merseyside	217	0 (0.0)	647	41 (6.3)	864	41 (4.7)
Cumbria and Lancashire	308	0 (0.0)	437	7 (1.6)	745	7 (0.9)
East Midlands	0	0 (0.0)	653	11 (1.7)	653	11 (1.7)
Greater Manchester	697	6 (0.9)	62	4 (6.5)	759	10 (1.3)
London	9	0 (0.0)	1,139	34 (3.0)	1,148	34 (3.0)
North East	584	1 (0.2)	187	6 (3.2)	771	7 (0.9)
Sussex, Surrey and Kent	654	5 (0.8)	658	28 (4.3)	1,312	33 (2.5)
Thames Valley	0	0 (0.0)	30	1 (3.3)	30	1 (3.3)
Wessex	746	4 (0.5)	115	2 (1.7)	861	6 (0.7)
West Midlands	787	10 (1.3)	1,142	18 (1.6)	1,929	28 (1.5)
Yorkshire and Humber	345	4 (1.2)	1,306	26 (2.0)	1,651	30 (1.8)
Total, all regions	4,734	31 (0.7)	6,961	187 (2.7)	11,695	218 (1.9)

* Dried blood spot testing only.

[§]Sentinel surveillance data excludes individuals aged less than one year, in whom positive tests may reflect the presence of passivelyacquired maternal antibody rather than true infection. Data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.

[†] Please note that testing data provided by Alere Toxicology Plc represents indicative results only and is not intended to be used for diagnosis. Some duplication of individuals may occur, aggregate numbers are supplied by Alere Toxicology Plc. therefore duplication checks could not be made and some individuals may have been tested more than once during the time period. All data are provisional.

b. Anti-HCV testing

Supplementary table 17. Number of individuals tested, and testing positive, for anti-HCV by dried blood spot, January – December 2013*

	Data from sentinel surveillance [§]		Data from Alere Toxicology Plc [†]		Total	
PHE centre of test request	Number tested	Number positive (%)	Number tested	Number reactive [†] (%)	Number tested	Number reactive (%)
Anglia and Essex	73	18 (24.7)	322	84 (26.1)	395	102 (25.8)
Avon, Gloucestershire and Wiltshire	326	37 (11.3)	207	56 (27.1)	533	93 (17.4)
Cheshire and Merseyside	35	1 (2.9)	529	156 (29.5)	564	157 (27.8)
Cumbria and Lancashire	329	79 (24.0)	334	90 (26.9)	663	169 (25.5)
East Midlands	0	0 (0.0)	597	192 (32.2)	597	192 (32.2)
Greater Manchester	794	139 (17.5)	206	77 (37.4)	1,000	216 (21.6)
London	10	0 (0.0)	803	173 (21.5)	813	173 (21.3)
North East	583	54 (9.3)	123	20 (16.3)	706	74 (10.5)
Sussex, Surrey and Kent	642	80 (12.5)	521	167 (32.1)	1,163	247 (21.2)
Thames Valley	0	0 (0.0)	99	26 (26.3)	99	26 (26.3)
Wessex	748	156 (20.9)	91	28 (30.8)	839	184 (21.9)
West Midlands	868	85 (9.8)	986	270 (27.4)	1,854	355 (19.1)
Yorkshire and Humber	272	80 (29.4)	1,092	310 (28.4)	1,364	390 (28.6)
Total, all regions	4,680	729 (15.6)	5,910	1,649 (27.9)	10,590	2,378 (22.5)

* Dried blood spot testing only.

[§]Sentinel surveillance data are de-duplicated subject to availability of date of birth, soundex and first initial. All data are provisional.
[†] Please note that testing data provided by Alere Toxicology Plc represents indicative results only and is not intended to be used for diagnosis. Some duplication of individuals may occur, aggregate numbers are supplied by Alere Toxicology Plc. therefore duplication checks could not be made and some individuals may have been tested more than once during the time period. All data are provisional.

c. HIV testing

Supplementary table 18. Number of individuals tested, and testing reactive, for HIV by dried blood spot, January – December 2013*

PHE centre	Number tested	Number positive (%) [†]
Anglia and Essex	292	0 (0.0)
Avon, Gloucestershire and Wiltshire	181	0 (0.0)
Cheshire and Merseyside	493	2 (0.4)
Cumbria and Lancashire	300	0 (0.0)
East Midlands	349	0 (0.0)
Greater Manchester	93	1 (1.1)
London	542	5 (0.9)
North East	65	1 (1.5)
Sussex, Surrey and Kent	389	2 (0.5)
Thames Valley	11	0 (0.0)
Wessex	29	0 (0.0)
West Midlands	749	0 (0.0)
Yorkshire and Humber	672	2 (0.3)
Total	4,165	13 (0.3)

* Dried blood spot testing only. Some duplication of individuals may occur, aggregate numbers are supplied by Alere Toxicology Plc. therefore duplication checks could not be made and some individuals may have been tested more than once during the time period. All data are provisional.

[†] Please note that testing data provided by Alere Toxicology Plc represents indicative results only and is not intended to be used for diagnosis.

9. Oral fluid testing

a. HBsAg testing

Supplementary table 19. Number of individuals tested, and testing reactive, for HBsAg by oral fluid, January – December 2013*

PHE centre	Number tested	Number positive (%) [†]
Anglia and Essex	78	0 (0.0)
Avon, Gloucestershire and Wiltshire	0	0 (0.0)
East Midlands	408	13 (3.2)
London	201	6 (3.0)
Wessex	45	0 (0.0)
West Midlands	8	0 (0.0)
Yorkshire and Humber	641	17 (2.7)
Total	1,381	36 (2.6)

* Oral fluid testing only. Some duplication of individuals may occur, aggregate numbers are supplied by Alere Toxicology Plc. therefore duplication checks could not be made and some individuals may have been tested more than once during the time period. All data are provisional.

[†] Please note that testing data provided by Alere Toxicology Plc represents indicative results only and is not intended to be used for diagnosis.

b. Anti-HCV testing

Supplementary table 20. Number of individuals tested, and testing reactive, for anti-HCV by oral fluid, January – December 2013*

PHE centre	Number tested	Number positive (%) [†]
Anglia and Essex	102	16 (15.7)
Avon, Gloucestershire and Wiltshire	0	0 (0.0)
East Midlands	307	37 (12.1)
London	178	32 (18.0)
Sussex, Surrey and Kent	3	1 (33.3)
Thames Valley	31	4 (12.9)
Wessex	102	17 (16.7)
West Midlands	20	3 (15.0)
Yorkshire and Humber	548	72 (13.1)
Total	1,291	182 (14.1)

* Oral fluid testing only. Some duplication of individuals may occur, aggregate numbers are supplied by Alere Toxicology Plc. therefore duplication checks could not be made and some individuals may have been tested more than once during the time period. All data are provisional.

provisional. [†] Please note that testing data provided by Alere Toxicology Plc represents indicative results only and is not intended to be used for diagnosis.

c. HIV testing

PHE centre	Number tested	Number positive (%) [†]
Anglia and Essex	119	0 (0.0)
East Midlands	264	0 (0.0)
London	25	0 (0.0)
Sussex, Surrey and Kent	3	0 (0.0)
Wessex	100	0 (0.0)
West Midlands	70	0 (0.0)
Yorkshire and Humber	684	0 (0.0)
Total	1,265	0 (0.0)

Supplementary table 21. Number of individuals tested, and testing reactive, for HIV by oral fluid, January – December 2013*

* Oral fluid testing only. Some duplication of individuals may occur, aggregate numbers are supplied by Alere Toxicology Plc. therefore duplication checks could not be made and some individuals may have been tested more than once during the time period. All data are provisional.

provisional. [†] Please note that testing data provided by Alere Toxicology Plc represents indicative results only and is not intended to be used for diagnosis.